We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $7.71M

70% more capital invested

Capital invested by funds: $87.5M → $149M (+$61.2M)

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

9% more funds holding

Funds holding: 91 → 99 (+8)

5.19% more ownership

Funds ownership: 29.99% → 35.18% (+5.2%)

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
31
Reduced
23
Closed
14
Calls
$13.5M
Puts
$7.71M
Net Calls
+$5.81M
Net Calls Change
+$8M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$3.4M
2
N
Nuveen
North Carolina
+$2.98M
3
Barclays
Barclays
United Kingdom
+$2.08M
4
SG Americas Securities
SG Americas Securities
New York
+$2M
5
State Street
State Street
Massachusetts
+$1.67M

Top Sellers

1
RI
RTW Investments
New York
-$4.15M
2
Deutsche Bank
Deutsche Bank
Germany
-$1.1M
3
CAC
Cowen and Company
New York
-$720K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$363K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPIA
76
Steward Partners Investment Advisory
New York
$30K – – –
Bank Julius Baer & Co
77
Bank Julius Baer & Co
Switzerland
$28K -$337 -101 -2%
Legal & General Group
78
Legal & General Group
United Kingdom
$28K +$946 +284 +5%
AIP
79
Ameritas Investment Partners
Nebraska
$26K – – –
CG
80
Cutler Group
California
$26K +$3.33K +1,000 +19%
TRCT
81
Tower Research Capital (TRC)
New York
$25K -$9.48K -2,844 -33%
SIAP
82
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$17K – – –
GWSG
83
GPS Wealth Strategies Group
Colorado
$10K – – –
PGAM
84
Princeton Global Asset Management
New Jersey
$9K – – –
PCM
85
Penserra Capital Management
California
$9K +$233 +70 +3%
GWM
86
Geneos Wealth Management
Colorado
$4K – – –
JWA
87
JFS Wealth Advisors
Pennsylvania
$4K – – –
AWA
88
Arkadios Wealth Advisors
Georgia
$4K +$3.33K +1,000 New
FDCDDQ
89
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.43K – – –
Federated Hermes
90
Federated Hermes
Pennsylvania
$3K -$1.71K -514 -45%
HI
91
Harbour Investments
Wisconsin
$3K +$1.67K +500 +250%
Koshinski Asset Management
92
Koshinski Asset Management
Illinois
$2.15K +$1.67K +500 New
HIA
93
Harbor Investment Advisory
Maryland
$2K – – –
PA
94
Parallel Advisors
California
$2K – – –
Daiwa Securities Group
95
Daiwa Securities Group
Japan
$1K – – –
NFG
96
Next Financial Group
Texas
$1K – – –
TF
97
TimeScale Financial
Massachusetts
$1K – – –
Walleye Capital
98
Walleye Capital
New York
$991 +$770K +231,037 New
Acadian Asset Management
99
Acadian Asset Management
Massachusetts
– -$361K -119,020 Closed
VF
100
Virtu Financial
New York
– -$282K -93,196 Closed
1 2 3
4
5

ABUS Hedge Fund Activity: Q3 2021 in Review

99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $149M — up 70% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ABUS positions and 14 closed out — a net gain of 9 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.

  • 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
  • Funds reported $149M of Arbutus Biopharma stock for Q3 2021, up 70% quarter-over-quarter.
  • 23 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +9 holders.
  • The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
  • The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.

Based on aggregated 13F filings for Q3 2021.